JP6580037B2 - 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン - Google Patents

高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン Download PDF

Info

Publication number
JP6580037B2
JP6580037B2 JP2016526515A JP2016526515A JP6580037B2 JP 6580037 B2 JP6580037 B2 JP 6580037B2 JP 2016526515 A JP2016526515 A JP 2016526515A JP 2016526515 A JP2016526515 A JP 2016526515A JP 6580037 B2 JP6580037 B2 JP 6580037B2
Authority
JP
Japan
Prior art keywords
cells
cytokines
cell
activity
ifnα2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016526515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016525516A (ja
JP2016525516A5 (enExample
Inventor
タヴェルニエール，ジャン
バルティンク，ジェニファー
ゲルロ，サラ
ユゼ，ギーユ
ポール，フランシアーヌ
ボルダ，ヤン
Original Assignee
ヴィブ ブイゼットダブリュー
ヴィブ ブイゼットダブリュー
ユニバーシテイト ヘント
ユニバーシテイト ヘント
ソントル ナショナル ド ラ ルシェルシュ シオンティフィック
ソントル ナショナル ド ラ ルシェルシュ シオンティフィック
ウニベルシテ ドゥ モンペリエ
ウニベルシテ ドゥ モンペリエ
ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ
ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴィブ ブイゼットダブリュー, ヴィブ ブイゼットダブリュー, ユニバーシテイト ヘント, ユニバーシテイト ヘント, ソントル ナショナル ド ラ ルシェルシュ シオンティフィック, ソントル ナショナル ド ラ ルシェルシュ シオンティフィック, ウニベルシテ ドゥ モンペリエ, ウニベルシテ ドゥ モンペリエ, ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ, ソントル オスピタリエ レジョナル ウニベルシテール ド モンペリエ filed Critical ヴィブ ブイゼットダブリュー
Publication of JP2016525516A publication Critical patent/JP2016525516A/ja
Publication of JP2016525516A5 publication Critical patent/JP2016525516A5/ja
Application granted granted Critical
Publication of JP6580037B2 publication Critical patent/JP6580037B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2016526515A 2013-07-18 2014-07-03 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン Active JP6580037B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13306034.3 2013-07-18
EP13306034 2013-07-18
PCT/EP2014/064227 WO2015007536A2 (en) 2013-07-18 2014-07-03 Fusokines involving cytokines with strongly reduced receptor binding affinities

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019154901A Division JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Publications (3)

Publication Number Publication Date
JP2016525516A JP2016525516A (ja) 2016-08-25
JP2016525516A5 JP2016525516A5 (enExample) 2017-08-10
JP6580037B2 true JP6580037B2 (ja) 2019-09-25

Family

ID=48906191

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016526515A Active JP6580037B2 (ja) 2013-07-18 2014-07-03 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン
JP2019154901A Active JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019154901A Active JP6853317B2 (ja) 2013-07-18 2019-08-27 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン

Country Status (14)

Country Link
US (3) US10640542B2 (enExample)
EP (2) EP3299466B1 (enExample)
JP (2) JP6580037B2 (enExample)
KR (1) KR102322510B1 (enExample)
CN (2) CN110835376B (enExample)
AU (2) AU2014292371B2 (enExample)
BR (1) BR112016001036B1 (enExample)
CA (1) CA2917937C (enExample)
DK (1) DK3299466T3 (enExample)
ES (2) ES2657060T3 (enExample)
IL (1) IL243451B (enExample)
MX (1) MX375441B (enExample)
SG (2) SG11201600163VA (enExample)
WO (1) WO2015007536A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017077382A1 (en) 2015-11-06 2017-05-11 Orionis Biosciences Nv Bi-functional chimeric proteins and uses thereof
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
CN116769054A (zh) 2016-02-05 2023-09-19 奥里尼斯生物科学私人有限公司 双特异性信号传导剂及其用途
EP4276114A3 (en) 2016-03-07 2024-02-21 Vib Vzw Cd20 binding single domain antibodies
US11753463B2 (en) 2016-05-13 2023-09-12 Orionis Biosciences BV Therapeutic targeting of non-cellular structures
US11236141B2 (en) 2016-05-13 2022-02-01 Orionis Biosciences BV Targeted mutant interferon-beta and uses thereof
JP7204643B2 (ja) 2016-10-24 2023-01-16 オリオニス バイオサイエンシズ ビーブイ 標的変異インターフェロン－ガンマおよびその使用
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
MX2019009255A (es) 2017-02-06 2019-11-05 Orionis Biosciences Nv Proteínas quiméricas dirigidas y sus usos.
WO2018146074A1 (en) 2017-02-07 2018-08-16 Vib Vzw Immune-cell targeted bispecific chimeric proteins and uses thereof
JP7423511B2 (ja) 2017-08-09 2024-01-29 オリオンズ バイオサイエンス インコーポレイテッド Ｐｄ－１およびｐｄ－ｌ１結合物質
WO2019032661A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. CD8 LIAISON AGENTS
BR112020002706A2 (pt) 2017-08-09 2020-08-25 Orionis Biosciences Inc. agentes de ligação a clec9a e uso dos mesmos
JP7551496B2 (ja) 2017-10-31 2024-09-17 カリヴィル イムノセラピューティクス， インコーポレイテッド 全身送達のためのプラットフォーム腫瘍溶解性ベクター
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
US12084497B2 (en) 2018-08-08 2024-09-10 Orionis Biosciences, Inc. SIRP1α targeted chimeric proteins and uses thereof
CA3118892A1 (en) 2018-11-08 2020-05-14 Orionis Biosciences, Inc. Modulation of dendritic cell lineages
JP7689079B2 (ja) 2019-03-28 2025-06-05 オリオニス バイオサイエンシズ，インコーポレイテッド 治療用インターフェロンアルファ１タンパク質
JP7773372B2 (ja) 2019-03-28 2025-11-19 オリオニス バイオサイエンシズ，インコーポレイテッド 線維芽細胞活性化タンパク質結合物質およびその使用
US12351614B2 (en) 2019-03-28 2025-07-08 Orionis Biosciences, Inc. CLEC9A-based chimeric protein complexes
US12544426B2 (en) 2019-06-19 2026-02-10 Orionis Biosciences, Inc. Combination therapy with CD13-targeted chimeric proteins or chimeric protein complexes
US20230293652A1 (en) * 2020-07-07 2023-09-21 Orionis Biosciences, Inc. Immunostimulatory adjuvants
PE20231175A1 (es) 2020-11-19 2023-08-01 Kalivir Immunotherapeutics Inc Inmunoterapia oncolitica por remodelacion del microambiente tumoral
IL316712B2 (en) * 2021-04-30 2025-12-01 Kalivir Immunotherapeutics Inc Oncolytic viruses for modified mhc expression
US20240166706A1 (en) * 2022-11-21 2024-05-23 Wisconsin Alumni Research Foundation Synthetic il6-il1beta fusion cytokine for promoting t cell cytotoxic function, t cell proliferation, and tumoricidal activity

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3115318B2 (ja) * 1989-08-22 2000-12-04 イミュネックス・コーポレーション Ｇｍ―ｃｓｆ及びｉｌ―３を含む融合タンパク質
US6277969B1 (en) 1991-03-18 2001-08-21 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US5914254A (en) 1993-08-02 1999-06-22 Celtrix Pharmaceuticals, Inc. Expression of fusion polypeptides transported out of the cytoplasm without leader sequences
BR0013231A (pt) * 1999-08-09 2002-07-23 Lexigen Pharm Corp Complexos citocina-anticorpo múltiplos
WO2002044394A2 (en) * 2000-11-29 2002-06-06 University Of Southern California Targetet retoviral vectors for cancer immunotherapy
CN1168740C (zh) * 2001-04-04 2004-09-29 上海美恩生物技术有限公司 细胞因子基因修饰的抗原提呈细胞/肿瘤细胞偶联物、其制法和用途
ATE542137T1 (de) * 2001-12-04 2012-02-15 Merck Patent Gmbh Immunocytokine mit modulierter selektivität
DE602004031341D1 (de) * 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
EP1812038A1 (en) 2004-11-18 2007-08-01 VIB vzw Fibronectin iii domain as leptin receptor antagonists
WO2006115800A2 (en) 2005-04-15 2006-11-02 The Regents Of The University Of California Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha
CA2693326A1 (en) 2006-08-02 2008-02-07 Mcgill University Gm-csf and il-15 fusokines and methods for modulation of the immune response
US11535673B2 (en) 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
EP2173377B1 (en) 2007-06-26 2017-11-29 University of Miami Antibody-endostatin fusion protein and its variants
CN101868246A (zh) 2007-09-21 2010-10-20 加利福尼亚大学董事会 被导靶的干扰素显示强的细胞凋亡和抗肿瘤活性
WO2010036918A2 (en) 2008-09-26 2010-04-01 University Of Massachusetts Intracellular dna receptor
CA2749558C (en) 2008-12-08 2019-01-15 Complix Nv Single-chain antiparallel coiled coil proteins
PE20120630A1 (es) 2009-08-17 2012-05-26 Roche Glycart Ag Inmunoconjugados dirigidos
JP2013504539A (ja) 2009-09-10 2013-02-07 サイトス バイオテクノロジー アーゲー 糖尿病治療におけるインターロイキン１βムテイン・コンジュゲートの使用
CA2779512C (en) * 2009-11-02 2017-01-17 Leonard H. Rome Vault complexes for cytokine delivery
EP2515916B1 (en) * 2009-12-23 2016-03-09 Gradalis, Inc. Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
CN102958531A (zh) * 2010-04-22 2013-03-06 耶路撒冷希伯来大学伊森姆研究发展公司 高亲和力瘦蛋白和瘦蛋白拮抗剂
CN102372780A (zh) * 2010-08-23 2012-03-14 上海市计划生育科学研究所 抗人绒毛膜促性腺激素抗体-白介素2融合蛋白的制备及其应用
EP2718457A4 (en) 2011-06-06 2014-12-24 Immungene Inc GENETICALLY MODIFIED FUSION MOLECULES LIGAND TNFSF-ANTIBODY ELEMENT
WO2013059885A2 (en) 2011-10-28 2013-05-02 Cephalon Australia Pty Ltd Polypeptide constructs and uses thereof
AU2013211059B8 (en) 2012-01-20 2017-12-21 Centre Hospitalier Regional Universitaire De Montpellier Targeted mutant alpha-helical bundle cytokines
CA2866126A1 (en) 2012-03-03 2013-09-12 Immungene, Inc. Engineered antibody-interferon mutant fusion molecules
UA125637C2 (uk) * 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b

Also Published As

Publication number Publication date
US12410222B2 (en) 2025-09-09
ES2757501T3 (es) 2020-04-29
BR112016001036B1 (pt) 2023-02-23
SG11201600163VA (en) 2016-02-26
CA2917937C (en) 2022-11-01
JP2020002155A (ja) 2020-01-09
CN105705641B (zh) 2021-07-13
JP2016525516A (ja) 2016-08-25
AU2014292371B2 (en) 2018-03-29
WO2015007536A2 (en) 2015-01-22
AU2018203868A1 (en) 2018-06-21
EP3022305A2 (en) 2016-05-25
BR112016001036A2 (pt) 2017-10-24
WO2015007536A3 (en) 2015-03-19
ES2657060T3 (es) 2018-03-01
CN105705641A (zh) 2016-06-22
US20190010199A1 (en) 2019-01-10
IL243451B (en) 2019-10-31
CN110835376B (zh) 2023-08-04
EP3299466B1 (en) 2019-09-11
MX375441B (es) 2025-03-06
DK3299466T3 (da) 2019-11-18
US20180155404A1 (en) 2018-06-07
CA2917937A1 (en) 2015-01-22
KR102322510B1 (ko) 2021-11-08
AU2018203868B2 (en) 2019-12-05
KR20160108291A (ko) 2016-09-19
US11358997B2 (en) 2022-06-14
EP3299466A1 (en) 2018-03-28
MX2016000611A (es) 2016-09-29
HK1252831A1 (en) 2019-06-06
IL243451A0 (en) 2016-03-31
CN110835376A (zh) 2020-02-25
AU2014292371A1 (en) 2016-02-04
EP3022305B1 (en) 2017-11-01
JP6853317B2 (ja) 2021-03-31
US20230054612A1 (en) 2023-02-23
SG10201808738WA (en) 2018-11-29
US10640542B2 (en) 2020-05-05

Similar Documents

Publication Publication Date Title
JP6853317B2 (ja) 高度に低下された受容体結合親和性を有するサイトカインを含むフソカイン
JP2021006038A (ja) 自己免疫疾患を治療するために調節性ｔ細胞を選択的に活性化する分子
ES2367027T3 (es) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
CN108602871A (zh) 用于治疗自身免疫疾病的选择性地活化调节性t细胞的分子
CN100503829C (zh) 白细胞介素-18突变体、其制品及应用
KR20170035910A (ko) 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 변형된 il-2 변이체
EP4253423A1 (en) Bispecific recombinant protein and use thereof
Kuziel et al. Interleukin-2 and the IL-2 Receptor: New Insight Into Structure and Function.
IL184423A (en) Homogeneous preparations of il-31, process for their production and formulations comprising them
CN108948207B (zh) 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用
WO2023070038A2 (en) Human il-12p40 variants and uses thereof
JP2024543991A (ja) Ｉｌ１０バリアントおよびその使用
HK1252831B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069A1 (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
HK1225069B (en) Fusokines involving cytokines with strongly reduced receptor binding affinities
JP3689111B2 (ja) インターロイキン１５
CN121666243A (zh) Il10反向单体

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170703

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190827

R150 Certificate of patent or registration of utility model

Ref document number: 6580037

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250